Review
Psychiatry
Amber N. Edinoff, Prithvi K. Doppalapudi, Claudia Orellana, Caroline Ochoa, Shelby Patti, Yahya Ghaffar, Elyse M. Cornett, Aaron J. Kaye, Omar Viswanath, Ivan Urits, Adam M. Kaye, Alan D. Kaye
Summary: Paliperidone palmitate is a long-acting injectable antipsychotic medication, with the 3-month formulation being more effective in preventing relapse in schizophrenic patients. Patients withdrawn from oral paliperidone, PP1M, or PP3M had varying risks of relapse, with PP1M showing the least risk.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Psychiatry
Hsue-Wei Chan, Chin-Yu Huang, Yung-Chieh Yen
Summary: Schizophrenia is a severe psychiatric disorder with poor medical adherence leading to high relapse rates. This retrospective cohort study found that paliperidone long-acting injection (PLAI) can effectively reduce the incidence of hospitalization and emergency room visits in patients with schizophrenia, demonstrating the potential benefits of PLAI in real-world settings.
Article
Clinical Neurology
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Maria Galeazzi, Paola Ferri, Sergio Rovesti, Alessandro Minarini
Summary: This study compared the efficacy and side effects of three different long-acting antipsychotic injections in patients with schizophrenia. The results showed that there was no significant difference among the three treatments in preventing relapses, improving quality of life, and satisfaction. However, weight increase was higher in patients receiving paliperidone palmitate one-monthly and paliperidone palmitate 3-monthly injections.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2022)
Article
Psychiatry
Petru Ifteni, Paula-Simina Petric, Andreea Teodorescu
Summary: This study introduced an index, ROLIN, for evaluating the opportunity for long-acting injectable antipsychotic initiation in patients with schizophrenia. The research found that 56% of patients had a strong indication for LAI treatment initiation. By examining the normal distribution of values, the study concluded that improving treatment for schizophrenia is crucial.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Psychiatry
Feng Wang, Juan Chen, Linglin Guo, Zhixiong Li, Zhe Li
Summary: This case report describes a 16-year-old girl with schizophrenia who experienced fluctuating psychotic symptoms during menstruation. Long-acting antipsychotic injections were used to control the symptoms and maintain medication consistency.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Health Care Sciences & Services
Chih-Sung Liang, Tung-Ping Su, Ming-Hsien Hsieh, Chau-Shoun Lee, Joseph Kuo, Nan-Ying Chiu, Po-See Chen, Yung-Chieh Yen, Ya-Mei Bai
Summary: The study developed nine consensus recommendations for safely switching from oral or long-acting injectable atypical antipsychotics to Aripiprazole long-acting once-monthly (AOM), including dose adjustment and considerations for pregnancy/breastfeeding. An 80% agreement among panel members was required for final adoption of the recommendations, highlighting the importance of expert consensus in guiding safe medication transitions.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Yu Chen, Mingchao Li, Qiuming Ji, Zou Su, Ziyu Yang, Yin Xu, Qian Chen, Dan Liao, Jihua Zeng, Yuhong Yang
Summary: The combination of paliperidone palmitate long-acting injection and electroacupuncture is more effective in treating methamphetamine addicts compared to electroacupuncture alone. It significantly improves withdrawal symptoms, anxiety, depression, and brain waves, leading to a reduced risk of relapse.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Olivier Corbeil, Anne-Marie Essiambre, Laurent Bechard, Audrey-Anne Roy, Maxime Huot-Lavoie, Sebastien Brodeur, Ranjith Chandrasena, Chantale Theriault, Candice Crocker, Jean-Pierre Melun, Phil Tibbo, Marie-France Demers, Marc-Andre Roy
Summary: The study aimed to evaluate the effectiveness of paliperidone palmitate 3-monthly (PP3M) in preventing relapse in patients with schizophrenia. The results showed that PP3M demonstrated good efficacy in reducing the risk of relapse. Patients with comorbid diagnoses of personality disorders and substance use disorders had a higher risk of relapse, and increased psychopathology severity was associated with an increased likelihood of relapse, while having a job or being in school was protective against relapse.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Zunkai Xu, Tao Liu, Yaoyao Jiang, Zhixia Chen, Xiaoguang Shi, Yang Xu, Na Yu, Xia Hua, Xing-Jie Liang, Xiaoyong Yuan, Shutao Guo
Summary: Injectable long-acting prodrug-based microcrystals with an acid-sensitive ketal linker were synthesized for developing extended-release antipsychotic drugs. The drug exposure was prolonged in rats treated with the prodrug-based microcrystals, and the release rate decreased with increasing microcrystal size. Moreover, the drug release from the microcrystals was considerably decreased in an inflammation model, indicating an immune-mediated boost in release post-injection.
MOLECULAR PHARMACEUTICS
(2022)
Review
Medical Laboratory Technology
Georgios Schoretsanitis, Pierre Baumann, Andreas Conca, Otto Dietmaier, Giancarlo Giupponi, Gerhard Grunder, Martina Hahn, Xenia Hart, Ursula Havemann-Reinecke, Gudrun Hefner, Maxim Kuzin, Rainald Moessner, Daria Piacentino, Werner Steimer, Gerald Zernig, Christoph Hiemke
Summary: Therapeutic drug monitoring in the treatment of long-acting injectable antipsychotics plays a key role, with individual differences, genetic specificity, and clinical variables potentially affecting drug concentrations. For switching from oral formulations to LAI formulations, therapeutic drug monitoring is a more accurate method for dose selection.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Pharmacology & Pharmacy
A. N. I. Kenar, G. A. Unal, A. Mert, A. M. Ay
Summary: The use of dual LAIA in chronic psychotic patients can effectively reduce hospitalizations and regularize medication use. This is particularly important for patients with poor social support and irregular medication use.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Article
Health Care Sciences & Services
Stephan Reymann, Georgios Schoretsanitis, Stephan T. Egger, Alexey Mohonko, Matthias Kirschner, Stefan Vetter, Philipp Homan, Erich Seifritz, Achim Burrer
Summary: Long-acting injectable antipsychotics (LAIs) offer benefits to patients with schizophrenia spectrum disorder (SSD), but the prescription rate of LAIs in a large academic psychiatric hospital in Switzerland is relatively low. Further research will investigate the reasons for this low rate.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Clinical Neurology
Stephen M. Stahl, Gorica Djokic
Summary: In this paper, the pharmacologic properties of antipsychotics and their role in explaining efficacy and tolerability differences are discussed. The use of plasma drug levels and long-acting injectables to improve compliance and manage treatment resistance is also reviewed.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, Greta Silvia Carnevali, Agnese Tringali, Roberto Nava, Massimo Clerici, Enrico Capuzzi
Summary: Treatment discontinuation is a challenge in clinical settings. Long acting injectable (LAI) antipsychotics are underutilized despite their potential benefits. This study aimed to identify the factors associated with LAI discontinuation in a real-world setting.
Article
Pharmacology & Pharmacy
Giuseppe Manini, Maud Deldime, Samira Benali, Jean-Marie Raquez, Jonathan Goole
Summary: This study utilized pressure extrusion-based printing (PEBP) as a 3D printing process to create long-acting implantable dosage forms, achieving different release profiles based on drug concentration, preparation method, and implant design. Polycaprolactone (PCL) was used as the polymer for sustained drug release, while Paliperidone palmitate (PP) served as the model drug with evaluations on different concentrations and preparation methods. Through PEBP printing, different implant designs were assessed for their impact on drug release profiles. Various characterization techniques were used for material preparation of long-acting implants.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Clinical Neurology
Shubhra Mace, Olubanke Dzahini, Victoria Cornelius, Hadar Langerman, Ebenezer Oloyede, David Taylor
Summary: This study found that patients prescribed clozapine had a higher risk of infection compared to those prescribed PPLAI. The incidence of infection was highest in the first 3 months of treatment for clozapine patients.
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Article
Clinical Neurology
Danielle Dunnett, Ebenezer Oloyede, Oluwakemi Oduniyi, Barbara Arroyo, Olubanke Dzahini, David Taylor, Sukhi S. Shergill, Eromona Whiskey
Summary: This study examined the clinical outcomes of patients prescribed penfluridol in an inner London National Health Service Trust over a one-year period. The results suggest that penfluridol, although unlicensed in the UK, has the potential to be used safely and effectively for treating psychotic disorders as a long-acting oral therapy. Further data are needed to establish the role of penfluridol and other long-acting oral antipsychotic formulations in psychotic disorder treatment.
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Article
Psychiatry
Graham Blackman, Ebenezer Oloyede, Mark Horowitz, Robert Harland, David Taylor, James MacCabe, Philip McGuire
Summary: There is currently no formal guidance on how to safely discontinue clozapine treatment, which poses risks of psychotic relapse and withdrawal symptoms.
SCHIZOPHRENIA BULLETIN
(2022)
Editorial Material
Psychiatry
David Taylor
ACTA PSYCHIATRICA SCANDINAVICA
(2022)
Review
Psychiatry
Cecilia Livermore, Hannah White, Loren Bailey, Ian Osborne, Ebenezer Oloyede, Olubanke Dzahini, Eromona Whiskey
Summary: The objective of this study was to explore the long-term effectiveness and tolerability of metoclopramide in the treatment of chronic intermittent headache. The results showed that metoclopramide may be an effective and tolerated drug in this condition, but more data is required to establish its place in pharmacotherapy.
Article
Clinical Neurology
Sofia Brissos, David Taylor
Summary: Maintaining compliance with antipsychotic treatment is crucial for managing schizophrenia, and long-acting injectables or supervised oral administration are effective strategies to ensure adherence to prescribed regimens. Different approaches are needed to address non-adherence issues in schizophrenia treatment.
Article
Psychiatry
Phoebe Wallman, Ivana Clark, David Taylor
Summary: This study suggests that rehospitalization is very uncommon and significantly reduced in patients stabilized on PP1M and switched to PP3M in normal clinical practice compared with previous treatments.
JOURNAL OF PSYCHIATRIC RESEARCH
(2022)
Article
Medicine, General & Internal
Giouliana Kadra-Scalzo, Deborah Ahn, Alex Bird, Matthew Broadbent, Chin-Kuo Chang, Megan Pritchard, Hitesh Shetty, David Taylor, Richard Hayes, Robert Stewart
Summary: This study compared mental healthcare use and healthcare professional contacts for patients before and after initiation of paliperidone palmitate, finding a decrease in inpatient bed days but longer active time in service case load for patients after initiation. Additionally, there was a decrease in face-to-face and telephone contacts with medical and social work HCPs, and an increase in contacts with clinical psychologists in the postinitiation period.
Article
Psychiatry
David Taylor, Kalliopi Vallianatou, Eromona Whiskey, Olubanke Dzahini, James MacCabe
Summary: The occurrence of agranulocytosis during clozapine treatment varies in severity, with some episodes being life-threatening while others are not. Monitoring schemes should focus on identifying true life-threatening agranulocytosis induced by clozapine.
Article
Psychiatry
Mark Abie Horowitz, David Taylor
Summary: Withdrawal symptoms from antidepressants are common and can be severe. It is difficult to distinguish withdrawal from relapse due to overlapping symptoms. However, by considering the timing of onset, the association of psychological and physical symptoms, the response to reinstatement, and the pattern of symptoms, it is possible to differentiate withdrawal from relapse. Current evidence for the relapse prevention properties of antidepressants is limited and needs re-evaluation.
Article
Psychiatry
Ebenezer Oloyede, Graham Blackman, Eromona Whiskey, Christian Bachmann, Olubanke Dzahini, Sukhi Shergill, David Taylor, Philip McGuire, James MacCabe
Summary: There is considerable variation in guidelines for monitoring hematological function in patients treated with clozapine globally. Standardizing guidelines for hematological monitoring worldwide would be beneficial.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
(2022)
Article
Psychiatry
Ebenezer Oloyede, Eromona Whiskey, Cecilia Casetta, Olubanke Dzahini, Danielle Dunnett, Shreyans Gandhi, Fiona Gaughran, Sukhi Shergill, Philip McGuire, James H. MacCabe, David Taylor
Summary: This study investigated the implications of implementing the US FDA monitoring criteria on clozapine use in the UK. The results showed that implementing the revised monitoring criteria would significantly reduce clozapine discontinuation for hematological reasons and greatly improve the mental health outcomes of these patients.
Article
Pharmacology & Pharmacy
Sofia Redaelli, Lilla Porffy, Ebenezer Oloyede, Olubanke Dzahini, Gabriella Lewis, Maria Lobo, Eromona Whiskey, Sukhi S. Shergill
Summary: Vortioxetine may be a potentially safe and effective option for adjunctive treatment in schizophrenia, with good tolerability for most patients, but further research is needed to confirm its effectiveness.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
E. Naomi Smith, Siobhan Gee, Gerri O'Brien, Pitchy-Ann Vicente, Rosemary Griffith, Rina Patel, Joshua Stapleton, Emily Finch, Naina Shah, Fiona Gaughran, David Taylor, John Strang, Nicola J. Kalk
Summary: The project aimed to provide vitamin D checks and replacement for patients with SUD, with results showing that the majority of patients had low levels of vitamin D and the frequency of checks and replacement has increased since the project began.